CL
VKTX icon

CSS LLC’s Viking Therapeutics VKTX Stock Holding History

CSS LLC’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-32,500
Closed -$306K – 902
2022
Q4 		$306K Buy
+32,500
New +$145K 0.02% 523
2021
Q1 		– Sell
-40,200
Closed -$226K – 1066
2020
Q4 		$226K Hold
40,200
– – 0.01% 612
2020
Q3 		$234K Hold
40,200
– – 0.01% 550
2020
Q2 		$290K Buy
40,200
+1,000
+3% +$6.64K 0.02% 445
2020
Q1 		$183K Buy
39,200
+31,700
+423% +$195K 0.01% 439
2019
Q4 		$60K Buy
+7,500
New +$54.7K ﹤0.01% 593

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CSS LLC's VKTX Position: Q4 2022 in Review

CSS LLC sold out of Viking Therapeutics (VKTX) in Q4 2022, closing a stake of 29,258 shares — an estimated $131K sold.

CSS LLC first reported a position in VKTX in Q4 2019 and held it in 12 quarters. The position peaked at $178K in Q1 2020. 129 funds tracked by Wall St. Rank hold VKTX as of Q4 2022.

  • CSS LLC reported no remaining Viking Therapeutics position as of Q4 2022 after selling out during the quarter.
  • CSS LLC sold 29,258 Viking Therapeutics shares in Q4 2022, an estimated $131K.
  • CSS LLC first reported a position in Viking Therapeutics in Q4 2019 and held it in 12 quarters.
  • CSS LLC's Viking Therapeutics position peaked at $178K in Q1 2020.
  • 129 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.